Enliven Therapeutics (NASDAQ:ELVN) Reaches New 1-Year High – Should You Buy?

Enliven Therapeutics, Inc. (NASDAQ:ELVN) reached a new 52-week high on Tuesday . The company traded as high as $30.66 and last traded at $30.6250, with a volume of 411864 shares. The stock had previously closed at $29.73.

Analyst Ratings Changes

Several equities analysts have issued reports on ELVN shares. Wall Street Zen cut shares of Enliven Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, February 28th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Wednesday, January 21st. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Stock Up 2.0%

The firm has a market capitalization of $1.81 billion, a PE ratio of -16.31 and a beta of 0.33. The stock has a 50-day simple moving average of $25.59 and a 200-day simple moving average of $21.96.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.06). Equities analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Insider Activity at Enliven Therapeutics

In other news, Director Richard A. Heyman sold 1,230 shares of the company’s stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $26.18, for a total value of $32,201.40. Following the sale, the director directly owned 22,647 shares of the company’s stock, valued at $592,898.46. This represents a 5.15% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Anish Patel sold 48,300 shares of the stock in a transaction on Friday, January 9th. The stock was sold at an average price of $27.99, for a total value of $1,351,917.00. Following the completion of the sale, the chief operating officer directly owned 215,011 shares in the company, valued at approximately $6,018,157.89. This represents a 18.34% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 227,180 shares of company stock worth $6,005,433 in the last three months. 25.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Enliven Therapeutics

Institutional investors have recently modified their holdings of the business. Commodore Capital LP increased its position in shares of Enliven Therapeutics by 0.4% during the 2nd quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock valued at $94,138,000 after purchasing an additional 17,809 shares during the last quarter. Vestal Point Capital LP lifted its holdings in shares of Enliven Therapeutics by 230.2% in the fourth quarter. Vestal Point Capital LP now owns 3,830,000 shares of the company’s stock worth $58,982,000 after buying an additional 2,670,000 shares in the last quarter. Polar Capital Holdings Plc increased its holdings in shares of Enliven Therapeutics by 13.5% in the fourth quarter. Polar Capital Holdings Plc now owns 3,513,680 shares of the company’s stock worth $54,111,000 after purchasing an additional 418,673 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock worth $52,260,000 after buying an additional 142,378 shares during the last quarter. Finally, State Street Corp increased its position in shares of Enliven Therapeutics by 9.1% during the 4th quarter. State Street Corp now owns 1,052,862 shares of the company’s stock valued at $16,214,000 after purchasing an additional 87,725 shares during the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.